US Prediction Markets Now Let Players Bet on Health Crises

Two major US prediction market platforms, Polymarket and Kalshi, have recently introduced betting contracts tied to public health events, including vaccine mandates, drug trial outcomes, and disease case numbers. This move opens new opportunities for players interested in prediction markets but also raises concerns about the implications for public health and consumer protection.

Users can now place wagers on when the US Food and Drug Administration (FDA) will approve a skin-cancer vaccine, whether the Centers for Disease Control and Prevention (CDC) will update vaccine recommendations, and the projected number of measles cases in the US for 2026. Both Kalshi and Polymarket have expanded their offerings to include these health-related contracts, which resemble traditional bets but are regulated under federal commodities laws rather than state gambling rules.

Experts warn that these markets carry distinct risks. Lia Nower, director of the Center for Gambling Studies at Rutgers University, described the current regulatory environment as “like the wild, wild west,” noting the absence of a federal body enforcing strict limits or minimum guidelines for prediction markets. This regulatory gap means players may engage in gambling-like activities without the usual consumer protections.

Matthew Eisenberg, chair of health policy at Johns Hopkins Bloomberg School of Public Health, pointed to concerns about insider information and market manipulation. He explained that prediction markets “create a payoff for anyone with nonpublic information,” such as FDA reviewers or drug trial investigators, which could incentivize leaks or behavior changes that influence trial outcomes. This raises ethical questions about the potential impact of these markets on public health decisions and drug development.

Players face risks including exposure to markets potentially influenced by insider knowledge or political actions. For example, lawmakers might bet on ending vaccine mandates while simultaneously advocating related legislation. Unlike regulated gambling platforms, these prediction markets currently lack robust safeguards against conflicts of interest or manipulation.

While Polymarket and Kalshi classify their contracts as financial derivatives rather than traditional bets, the practical effect for consumers is similar to gambling. Several states have filed lawsuits alleging these platforms operate as unlicensed gambling sites, but the legal situation remains unsettled.

Prediction markets fall under the oversight of the US Commodity Futures Trading Commission (CFTC), which regulates commodities and derivatives rather than traditional gambling. This regulatory loophole allows platforms to offer contracts on a wide range of events, including health outcomes, without the stricter controls that govern state-licensed gambling operations.

Concerns also exist about participants influencing outcomes. For instance, drug trial volunteers might alter their behavior to sway results, or companies could adjust trial timing based on market activity. Such dynamics could undermine the integrity of public health data and regulatory decisions.

Players interested in these markets should be aware of the potential for unpredictable outcomes influenced by nonpublic information and the absence of standard gambling protections. Cautious engagement is advisable, especially given the sensitive nature of the health topics involved.

For more on prediction markets and player protections, see our coverage on Betting and USA gambling news. Additional context on regulatory challenges can be found in recent reports on the Michigan Gaming Control Board’s crackdown on illegal gambling operations, highlighting the importance of player protection in evolving markets (CDC Gaming).

Read the full report from The Guardian for detailed insights: Health is wealth? Polymarket and Kalshi now host bets on measles and other US health crises.

David Rossi